Parenteral ascorbic acid in haemodialysis patients

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 11, Issue 6, 2008, Pages 741-746

  Biesalski, Hans K ^a  

^a UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

Etythropoetin resistance; Haemodialysis; Iron overload; Oxalosis; Vitamin C

Indexed keywords

ASCORBIC ACID; DEFEROXAMINE; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; IRON; IRON COMPLEX; OXALIC ACID; RECOMBINANT ERYTHROPOIETIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ASCORBIC ACID DEFICIENCY; BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; HYPEROXALEMIA; HYPEROXALURIA; IRON DEFICIENCY ANEMIA; IRON KINETICS; IRON OVERLOAD; IRON THERAPY; LOW DRUG DOSE; OXIDATION; PATIENT COMPLIANCE; PATIENT MONITORING; RECOMMENDED DRUG DOSE; RETICULOENDOTHELIAL SYSTEM; REVIEW; SUBSTITUTION THERAPY; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; DRUG RESISTANCE; ERYTHROPOIETIN; HEMOSIDEROSIS; HUMANS; INFLAMMATION; INFUSIONS, PARENTERAL; RENAL DIALYSIS;

EID: 55149122204     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32830f2256     Document Type: Review

References (35)

1. Singer R, Rhodes HC, Chin G, et al. High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. Nephrology (Carlton) 2008; 13:17-22.
2. Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial 2001; 14:348-356.
3. Durose CL, Holdsworth M, Watson V, Przygrodzka F. Knowledge of dietary restrictions and the medical consequences of noncompliance by patients on hemodialysis are not predictive of dietary compliance. J Am Diet Assoc 2004; 104:35-41.
4. Rahmati MA, Craig RG, Homel P, et al. Serum markers of periodontal disease status and inflammation in haemodialysis patients. Am J Kidney Dis 2002; 40:983-989.
5. Khajehdehi P, Mojerlou M, Behzadi S, Rais-Jalali GA. A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps. Nephrol Dial Transplant 2001; 16:1448-1451.
6. Langlois V, Geary D, Murray L, et al. Polyuria and proteinuria in cystinosis have no impact on renal transplantation. A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 2000; 15:7-10.
7. Richter A, Kuhlmann MK, Seibert E, et al. Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients. Nephrol Dial Transplant 2008; 23:2058-2063.
8. Morena M, Cristol JP, Bosc JY, et al. Corrective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 2002; 17:422-427.
9. Suva J, Andrade S, Ventura H, et al. Iron supplementation in haemodialysis - practical clinical guidelines. Nephrol Dial Transplant 1998; 13:2572-2577.
10. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for Erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998; 13:2867-2872.
11. Erhardt JG, Estes JE, Reifer CM, et al. Nutritional methodology. Combined measurement of ferritin, soluble transferrin receptor, retinol binding protein, and C-reactive protein by an inexpensive, sensitive, and simple sandwich enzyme-linked immunosorbent assay technique. J Nutr 2004; 134:3127-3132.
12. Wang S, Geraci G, Kuhlmann MK, et al. Chemical reactions of vitamin C with intravenous-iron formulations. Nephrol Dial Transplant 2008; 23:120-125. Different kinds of i.v. iron and interactions with ascorbic acid.
13. Derman D, Sayers M, Lynch SR, et al. Iron absorption from a cereal-based meal containing cane sugar fortified with ascorbic acid. Br J Nutr 1977; 38:261-269.
14. Mircescu G, Gârneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in predialyzed chronic renal failure patients. Nephrol Dial Transplant 2006; 21:120-124.
15. Tarng DC, Hung SC, Huang TP. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in haemodialysis patients. J Am Soc Nephrol 2004; 15:2486-2493.
16. Sturm B, Laggner H, Ternes N, et al. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron. Kidney Int 2005; 67:1161-1170.
17. Keven K, Kutlay S, Nergizoglu G, Ertürk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41:1233-1239.
18. Tarng DC, Wei YH, Huang TP, et al. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in haemodialysis patients with hyperferritinemia. Kidney Int 1999; 55:2477-2486.
19. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 2006; 47:644-654.
20. Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42:761-773.
21. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem 2008; 41:381-386. Well designed study to evaluate antioxidant status and effects of i.v. vitamin C
22. Deira J, Diego J, Martínez R, et al. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol 2003; 16:703-709.
23. Fishbane S. EPO adjuvant treatments: a need for more evidence [editorial]. Am J Kidney Dis 2006; 47:683-685.
24. Mühlhöfer A, Mrosek S, Schlegel B, et al. High-dose intravenous vitamin C is not associated with an increase of pro-oxidative biomarkers. Eur J Clin Nutr 2004; 58:1151-1158.
25. Moriwaki K, Kanno Y, Nakamoto H, et al. Vitamin B6 deficiency in elderly patients on chronic peritoneal dialysis. Adv Perit Dial 2000; 16:308-312.
26. Ogawa Y, Machida N, Johana M, et al. Major factors modulating the serum oxalic acid level in hermodialysis patients. Front Biosci 2004; 9:2901-2908.
27. Hirano H, Tone Y, Otani H, et al. Levels of serum ascorbate and its metabolites in hermodialysis patients. Nippon Jinzo Gakkai Shi 2004; 46:426-433.
28. Deicher R, Ziai F, Bieglmayer C, et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:1811-1818.
29. Canavese C, Marangella M, Stratta P. Think of oxalate when using ascorbate supplementation to optimize iron therapy in dialysis patients. Nephrol Dial Transplant 2008; 23:1463-1464. Important study with respect to toxicological concerns.
30. Ogi M, Abe R, Nishitani T, et al. The oxalate level in ultrafiltrate fluid collected from a dialyzer is useful for estimating the plasma oxalate level in hemodialysis patients. Clin Exp Nephrol 2006; 10:118-123.
31. Marangella M, Vitale C, Petrarulo M, et al. Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int 1995 ; 48:182-187.
32. Schäfer RM. Author reply. Nephrol Dial Transplant 2008; 23:1464.
33. Schäfer L, Schäfer RM. A primer on iron therapy. Nephrol Dial Transplant 2007; 22:2429-2431.
34. Chan D, Irish A, Dogra G. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton) 2005; 10:33-40.
35. Levine M, Rumsey SC, Daruwala R. Criteria and recommendations for vitamin C intake. JAMA 1999; 281:1415-1423.